Jobs
岗位职责:
- 负责生化分析仪器新设备安装调试、验证工作,包括起草设备标准操作规程,能解决仪器常见问题;
- 负责执行生化分析方法优化、转移、验证及日常分析的工作;分析方法包含但不局限于结合活性、HCP、Protein A、DNA等;
- 负责产品的稳定性研究;
- 根据SOP完成测试,保证实验过程和结果的及时性和准确性;
- 负责生化实验室试剂耗材的管理和维持现场6S;
- 严格遵守公司EHS安全法规,掌握安全工作技能和应急救援知识;
- 保持QC实验室的高GMP合规性和DI。
- 负责配合生化主管完成实验室发生的偏差、OOS/OOE/OOT等的调查,严格按照CAPA要求实施;
- 协助部门按时完成项目进度;
- 跟踪和熟悉国内外关于生物分析方法相关的法规和指南要求;
- 担任培训新员工的教练角色。
任职要求:
- 本科以上学历,生物化学,生物分析,生物技术等专业背景;
- 至少2年以上抗体生化分析的相关工作经验;
- 理解酶标仪和Q-PCR仪的工作原理,熟练使用结合活性,HCP,Protein A和DNA 等方法对大分子进行生化分析;
- 熟悉现行版《中国药典》、《欧洲药典》、《美国药典》、GMP等相关法律法规;
- 能在cGMP环境中独立执行分析工作,并最大限度地减少实验室误差;
- 具备良好的职业素养和团队协助能力;
- 熟悉企业现代化管理,熟练使用MS-Word, MS-Excel, MS-Outlook等办公软件。
Total Views
0
Apply Clicks
0
Weekly mock applicants
0
Bookmarks
0
Similar jobs
About BioNTech

BioNTech
PublicBioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
1,001-5,000
Employees
Mainz that develops immunotherapies
Headquarters
$21.7B
Valuation
Reviews
4.0
10 reviews
Work-life balance
2.5
Compensation
3.8
Culture
4.2
Career
3.5
Management
3.2
75%
Recommend to a friend
Pros
Innovative and cutting-edge projects
Great team and collaborative environment
Excellent benefits and flexible schedule
Cons
Long working hours and high workload
Fast-paced and high-pressure environment
Management and communication issues
Salary Ranges
70 data points
L2
L3
L4
L5
L6
Mid/L4
Intern
L2 · Data Scientist L2
0 reports
$53,767
total per year
Base
$21,507
Stock
$26,884
Bonus
$5,377
$37,637
$69,897
Interview experience
1 interviews
Difficulty
3.0
/ 5
Duration
14-28 weeks
Interview process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Interview
6
Offer
Common questions
Behavioral/STAR
Technical Knowledge
Past Experience
Culture Fit
Problem Solving
News & Buzz
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
Oncodaily
News
·
1d ago
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story - simplywall.st
simplywall.st
News
·
3d ago
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
medwatch.com
News
·
6d ago
BioNTech and DualityBio report positive data for trastuzumab pamirtecan - Clinical Trials Arena
Clinical Trials Arena
News
·
6d ago




